SPERO THERAPEUTICS INC (SPRO)
US84833T1034 - Common Stock
We assign a fundamental rating of 4 out of 10 to SPRO. SPRO was compared to 561 industry peers in the Biotechnology industry. SPRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, SPRO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SPRO was profitable.
In the past year SPRO has reported a negative cash flow from operations.
SPRO had negative earnings in 4 of the past 5 years.
In the past 5 years SPRO always reported negative operating cash flow.
1.2 Ratios
SPRO's Return On Assets of 2.60% is amongst the best of the industry. SPRO outperforms 93.51% of its industry peers.
With an excellent Return On Equity value of 5.36%, SPRO belongs to the best of the industry, outperforming 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 5.36% | ||
| ROIC | N/A |
ROA(3y)-25.72%
ROA(5y)-37.19%
ROE(3y)-47.16%
ROE(5y)-56.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SPRO's Profit Margin of 3.30% is amongst the best of the industry. SPRO outperforms 93.87% of its industry peers.
The Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.3% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRO has been increased compared to 1 year ago.
The number of shares outstanding for SPRO has been increased compared to 5 years ago.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.53, we must say that SPRO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.53, SPRO perfoms like the industry average, outperforming 49.01% of the companies in the same industry.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.53 |
ROIC/WACCN/A
WACC10.63%
2.3 Liquidity
SPRO has a Current Ratio of 2.68. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
SPRO's Current ratio of 2.68 is on the low side compared to the rest of the industry. SPRO is outperformed by 69.19% of its industry peers.
A Quick Ratio of 2.68 indicates that SPRO has no problem at all paying its short term obligations.
The Quick ratio of SPRO (2.68) is worse than 67.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.68 |
3. Growth
3.1 Past
SPRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.36%.
SPRO shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.01%.
Measured over the past years, SPRO shows a very strong growth in Revenue. The Revenue has been growing by 92.07% on average per year.
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)37.01%
Revenue growth 3Y123.23%
Revenue growth 5Y92.07%
Sales Q2Q%-47.12%
3.2 Future
SPRO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.16% yearly.
SPRO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.10% yearly.
EPS Next Y-307.92%
EPS Next 2Y-84.59%
EPS Next 3Y-42%
EPS Next 5Y1.16%
Revenue Next Year-24.43%
Revenue Next 2Y-36.04%
Revenue Next 3Y-49.62%
Revenue Next 5Y7.1%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.43 indicates a correct valuation of SPRO.
Based on the Price/Earnings ratio, SPRO is valued cheaper than 96.58% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.40, SPRO is valued a bit cheaper.
SPRO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.43 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as SPRO's earnings are expected to decrease with -42.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.59%
EPS Next 3Y-42%
5. Dividend
5.1 Amount
No dividends for SPRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SPERO THERAPEUTICS INC
NASDAQ:SPRO (1/6/2025, 5:56:16 PM)
1.08
-0.02 (-1.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners26.11%
Inst Owner Change0%
Ins Owners4.5%
Ins Owner Change-1.6%
Market Cap58.88M
Analysts80
Price Target5.1 (372.22%)
Short Float %1.05%
Short Ratio1.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.26%
Min EPS beat(2)13.65%
Max EPS beat(2)14.86%
EPS beat(4)3
Avg EPS beat(4)156.67%
Min EPS beat(4)-443.03%
Max EPS beat(4)1041.18%
EPS beat(8)7
Avg EPS beat(8)257.83%
EPS beat(12)8
Avg EPS beat(12)169.33%
EPS beat(16)10
Avg EPS beat(16)128.51%
Revenue beat(2)2
Avg Revenue beat(2)139.14%
Min Revenue beat(2)72.24%
Max Revenue beat(2)206.03%
Revenue beat(4)3
Avg Revenue beat(4)126.83%
Min Revenue beat(4)-57.81%
Max Revenue beat(4)286.85%
Revenue beat(8)7
Avg Revenue beat(8)116%
Revenue beat(12)8
Avg Revenue beat(12)72.28%
Revenue beat(16)10
Avg Revenue beat(16)57.72%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.09%
EPS NY rev (1m)-6.8%
EPS NY rev (3m)20.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-56.52%
Revenue NY rev (1m)7.02%
Revenue NY rev (3m)90.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.43 | ||
| Fwd PE | N/A | ||
| P/S | 0.55 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.9 | ||
| P/tB | 0.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.07
EY6.48%
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS1.95
BVpS1.2
TBVpS1.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 5.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3.3% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.72%
ROA(5y)-37.19%
ROE(3y)-47.16%
ROE(5y)-56.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.68 | ||
| Altman-Z | -2.53 |
F-Score5
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next Y-307.92%
EPS Next 2Y-84.59%
EPS Next 3Y-42%
EPS Next 5Y1.16%
Revenue 1Y (TTM)37.01%
Revenue growth 3Y123.23%
Revenue growth 5Y92.07%
Sales Q2Q%-47.12%
Revenue Next Year-24.43%
Revenue Next 2Y-36.04%
Revenue Next 3Y-49.62%
Revenue Next 5Y7.1%
EBIT growth 1Y-152.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.96%
OCF growth 3YN/A
OCF growth 5YN/A